Amount of qualified sufferers: CDEC reviewed the uncertainty in the amount of sufferers with reasonably extreme to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or moderate disease can have a critical bleeding https://chesteru461smp5.activoblog.com/profile